Allogene Therapeutics
Allogene Therapeutics' revenue fell 100.0% to $0 million in fiscal 2025. Free cash flow was −$150 million. The diluted share count rose 13.2%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Allogene Therapeutics does
Allogene is a clinical-stage company, which means it has no approved products yet. It is developing cancer and autoimmune treatments made from genetically engineered T cells, a type of immune cell. Its cells come from healthy donors and are meant to be used for any patient, instead of being made from each patient's own cells.
The company has three main programs: a lymphoma treatment (cema-cel) in a trial called ALPHA3, a treatment for autoimmune disease (ALLO-329), and a kidney cancer treatment (ALLO-316). It uses gene-editing technology licensed from Cellectis and Arbor Biotechnologies to reduce the risk that the donor cells attack the patient's healthy tissue.
Allogene reports no product sales. It pays for its research with money it raises, and it says it will need substantial additional financing. It was founded by executives who previously worked at Kite Pharma, a cell therapy company now owned by Gilead.
Its biggest risks, as it describes them
- Net losses since its start, and a need for substantial new financing to keep developing its treatments.
- Its treatments use new technology, so trial results, timing and regulatory approval are hard to predict.
- Heavy dependence on a few lead product candidates and on partners such as Cellectis and Servier.
- Safety events in its lymphoma trial could lead to regulatory action or product liability claims.
Income statement
Allogene Therapeutics lost money in fiscal 2025: a net loss of $191 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 810 | 576 | 449 | 373 | 258 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | −1,509.4x | −194.7x |
| Current ratio | 9.8x | 9.8x | 12.4x | 8.5x | 7.9x |
| Quick ratio | 9.8x | 9.8x | 12.4x | 8.5x | 7.9x |
Cash flow
Projections
Project Allogene Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
What Allogene Therapeutics says to expect
- Full year 2026: operating expenses
Guidance for operating expense in 2026 is expected to be approximately $165 million. GAAP Operating Expenses are expected to be approximately $225 million, including estimated non-cash stock-based compensation expense of approximately $35 million. These estimates exclude any impact from potential business development activities.
- ALPHA3 trial: next update and enrollment timing
The Company continues to anticipate its next clinical update in mid-2027, with trial enrollment expected to be completed by year-end 2027.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Allogene Therapeutics shares on the open market, and 6 insiders sold $619,156.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 21, 2026 | Earl Martin DouglasSVP, General Counsel | Sold | 29,697 | $2.12 | $62,958 | Form 4 |
| Apr 21, 2026 | Annie YoshiyamaSVP, Finance | Sold | 9,586 | $2.31 | $22,144 | Form 4 |
| Mar 31, 2026 | Benjamin Machinas BeneskiSVP, Chief Technical Officer | Sold | 2,867 | $2.50 | $7,168 | Form 4 |
| Mar 16, 2026 | David D ChangPresident and CEO, Director | Sold | 47,763 | $2.47 | $117,975 | Form 4 |
| Mar 16, 2026 | Benjamin Machinas BeneskiSVP, Chief Technical Officer | Sold | 4,835 | $2.47 | $11,942 | Form 4 |
| Mar 2, 2026 | Benjamin Machinas BeneskiSVP, Chief Technical Officer | Sold | 7,132 | $2.60 | $18,543 | Form 4 |
| Feb 2, 2026 | David D ChangPresident and CEO, Director | Sold | 95,269 | $1.80 | $171,484 | Form 4 |
| Feb 2, 2026 | Zachary RobertsEVP of R&D | Sold | 35,700 | $1.77 | $63,189 | Form 4 |
| Feb 2, 2026 | Geoffrey M. ParkerChief Financial Officer | Sold | 24,001 | $1.76 | $42,242 | Form 4 |
| Feb 2, 2026 | Earl Martin DouglasSVP, General Counsel | Sold | 22,900 | $1.76 | $40,304 | Form 4 |
| Feb 2, 2026 | Benjamin Machinas BeneskiSVP, Chief Technical Officer | Sold | 7,549 | $1.73 | $13,060 | Form 4 |
| Feb 2, 2026 | Annie YoshiyamaSVP, Finance | Sold | 4,167 | $1.72 | $7,167 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | −251,880.2% | −913,685.9% | — |
| Altman Z'' | −2.92 | −7.45 | −13.10 |
| Accruals ratio | −12.2% | −9.6% | −8.6% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Fail | Fail |
| F-score | — | — | — |
Compare
Put Allogene Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Allogene Therapeutics | FY25 | −100.0% | — | — | — | — | — | |
| AbbVie | FY25 | 8.6% | 24.6% | 29.1% | 15.7% | 2.7x | 7 | Compare |
| AbCellera Biologics | FY25 | 160.6% | −289.0% | −231.7% | — | — | — | Compare |
| Abeona Therapeutics | FY25 | — | −1,536.9% | −1,448.5% | — | — | — | Compare |
| Absci | FY25 | −38.2% | −4,297.0% | −3,358.3% | −162.8% | — | 3 | Compare |
8 years of figures
| Fiscal year | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | 0 | 0 | 114 | 0 | 0 | 0 | 0 |
| Revenue growth | — | — | — | — | −99.9% | −39.1% | −76.8% | −100.0% |
| Gross profit | — | — | — | — | — | — | — | — |
| Research and development | 152 | 144 | 193 | 220 | 256 | 243 | 192 | 150 |
| Operating income | −193 | −202 | −258 | −180 | −336 | −328 | −273 | −209 |
| Net income | −212 | −185 | −316 | −182 | −340 | −327 | −258 | −191 |
| Diluted EPS (US$) | −7.31 | −1.83 | −2.63 | −1.34 | −2.38 | −2.09 | −1.32 | −0.87 |
| Diluted shares (millions) | 29 | 101 | 120 | 136 | 143 | 157 | 195 | 221 |
| Cash flow | ||||||||
| Cash from operations | −45 | −137 | −115 | −185 | −220 | −238 | −200 | −149 |
| Capital expenditure | 3 | 51 | 66 | 21 | 5 | 2 | 1 | 0 |
| Free cash flow | −48 | −188 | −181 | −206 | −226 | −239 | −201 | −150 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 19 | 46 | 65 | 81 | 84 | 66 | 52 | 38 |
| Balance sheet at fiscal year end | ||||||||
| Cash and short-term investments | 721 | 589 | 1,000 | 810 | 576 | 449 | 373 | 258 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — |
| Total assets | 774 | 718 | 1,228 | 1,051 | 822 | 643 | 549 | 416 |
| Total liabilities | 71 | 89 | 148 | 126 | 155 | 131 | 126 | 123 |
| Shareholders' equity | 703 | 629 | 1,014 | 925 | 667 | 512 | 422 | 292 |
| Margins and ratios | ||||||||
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | −157.9% | −215,087.2% | −344,986.3% | −1,241,813.6% | — |
| Net margin | — | — | — | −159.6% | −218,214.1% | −344,489.5% | −1,170,863.6% | — |
| Free cash flow margin | — | — | — | −180.8% | −144,685.9% | −251,841.0% | −913,609.1% | — |
| Rule of 40 (growth + FCF margin) | — | — | — | — | −144,785.8% | −251,880.2% | −913,685.9% | — |
| Return on capital | — | — | — | — | — | — | — | — |
| Return on equity | — | −27.7% | −38.5% | −18.8% | −42.8% | −55.5% | −55.1% | −53.4% |
| Return on assets | — | −24.8% | −32.5% | −16.0% | −36.4% | −44.7% | −43.2% | −39.6% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — |